Product Description
Mechanisms of Action: TK Inhibitor,EGFR Inhibitor,Btk Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Israel
Approved Indications: None
Known Adverse Events: None
Company: Hanmi Company Limited
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Phase 1: Healthy Volunteers|Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HM-EMSI-202 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2020-12-08 |
55% |
| 2015-001435-21 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2020-03-18 |
|
| ELUXA 2 | P3 |
Completed |
Non-Small-Cell Lung Cancer |
2019-12-05 |
|
| HM-EMSI-103 | P1 |
Terminated |
Non-Small-Cell Lung Cancer |
2018-12-11 |
41% |